All In Biotech

Drug Trial Radar · NCT07223671

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Repotrectinib on the Pharmacokinetics of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Dec 31, 2025

Primary completion

Feb 19, 2026

Study completion Mar 19, 2026

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study if to evaluate the effect of Repotrectinib on the drug levels of transporter and CYP P450 probe substrates in healthy adult participants.

Conditions

  • Healthy Volunteers

Interventions

  • RepotrectinibDrug

    Specified dose on specified days

  • MetforminDrug

    Specified dose on specified days

  • DigoxinDrug

    Specified dose on specified days

  • RosuvastatinDrug

    Specified dose on specified days

  • BupropionDrug

    Specified dose on specified days

  • FlurbiprofenDrug

    Specified dose on specified days

  • OmeprazoleDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of AUC (0-T) of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
  2. Cohort 1: AUC (0-T) of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose
  3. Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
  4. Cohort 1: AUC(INF) of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose
  5. Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
  6. Cohort 1: Cmax of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose
  7. Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to 48 Hours Post Dose (AUC (0-48)) of Metformin With RepotrectinibTime frame: Up to approximately Day 17 post dose
  8. Cohort 1: AUC (0-48) of Metformin Without RepotrectinibTime frame: Up to approximately Day 17 post dose
  9. Cohort 1: Renal Clearance (CLR) of Metformin in UrineTime frame: Up to approximately Day 16 post dose
  10. Cohort 2: AUC (0-T) of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
  11. Cohort 2: AUC (0-T) of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose
  12. Cohort 2: AUC (INF) of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
  13. Cohort 2: AUC (INF) of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose
  14. Cohort 2: Cmax of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
  15. Cohort 2: Cmax of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0001

    Daytona Beach, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.